Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.74 |
| ▸ | CA12 | O43570 | 3/20 | 0.68 |
| ▸ | CA2 | P00918 | 3/20 | 0.68 |
| ▸ | CA4 | P22748 | 3/20 | 0.68 |
| ▸ | CA6 | P23280 | 3/20 | 0.68 |
| ▸ | CA5A | P35218 | 3/20 | 0.68 |
| ▸ | CA7 | P43166 | 3/20 | 0.68 |
| ▸ | CA9 | Q16790 | 3/20 | 0.68 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.68 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | F13A1 | P00488 | 2/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.68 |
| ▸ | THPO | P40225 | 2/20 | 0.68 |
| ▸ | CASP2 | P42575 | 2/20 | 0.68 |
| ▸ | RECQL | P46063 | 1/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.68 |
| ▸ | GLA | P06280 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9327511 | 0.97 | CYP2C19 (0.70) | CYP2C19CYP1A2CA12CA2CA4 | |
| SCHEMBL10045210 | 0.97 | CYP2C19 (0.70) | CYP2C19CYP1A2CA12CA2CA4 | |
| SCHEMBL14619485 | 0.97 | CYP2C19 (0.70) | CYP2C19CYP1A2CA12CA2CA4 | |
| SCHEMBL10081835 | 0.97 | CYP2C19 (0.72) | CYP2C19CYP1A2CA12CA2CA4 | |
| SCHEMBL5386129 | 0.97 | CYP1A2 (0.72) | CYP2C19CYP1A2CA12CA2CA4 | |
| Hydrochloric Acid SCHEMBL8851977 | 0.95 | CYP2C19 (0.67) | CYP2C19CYP1A2CA12CA2CA4 | |
| SCHEMBL29753241 | 0.95 | CYP2C19 (0.68) | CYP2C19CYP1A2CA12CA2CA4 | |
| SCHEMBL5386125 | 0.95 | CYP2C19 (0.74) | CYP2C19CYP1A2CA12CA2CA4 | |
| SCHEMBL10045119 | 0.95 | CYP2C19 (0.74) | CYP2C19CYP1A2CA12CA2CA4 | |
| SCHEMBL29054916 | 0.95 | CYP2C19 (0.68) | CYP2C19CYP1A2CA12CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 278 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101300004-A | Methods of treating viral infections using polyamine analogs | PATHOLOGICA LLC (US) | 2008-11-05 | — | — | CN | claimed |
| EP-4497478-A2 | USE OF POLYAMINES IN COMPOSITIONS AND METHODS FOR INDUCING OR PROMOTING SKIN DARKENING AND REGULATING MELANOGENESIS | Agency for Science, Technology and Research (SG) | 2025-01-29 | — | — | EP | disclosed |
| EP-3509576-B1 | USE OF POLYAMINES IN COMPOSITIONS AND METHODS FOR INDUCING OR PROMOTING SKIN DARKENING AND REGULATING MELANOGENESIS | AGENCY SCIENCE TECH & RES (SG) | 2024-10-30 | — | — | EP | disclosed |
| EP-4381070-A2 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES | Phio Pharmaceuticals Corp. (US) | 2024-06-12 | — | — | EP | disclosed |
| CN-118043459-A | Chemically modified oligonucleotides | 菲奥医药公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2024064769-A1 | INDUCTION OF STEM-LIKE ACTIVATED T CELLS | PHIO PHARMACEUTICALS CORP. (US) | 2024-03-28 | — | — | WO | disclosed |
| US-11926828-B2 | Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1 | PHIO PHARMACEUTICALS CORP. (US) | 2024-03-12 | — | — | US | disclosed |
| WO-2023130021-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES WITH IMPROVED DELIVERY PROPERTIES | PHIO PHARMACEUTICALS CORP. (US) | 2023-07-06 | — | — | WO | disclosed |
| US-11667915-B2 | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality | PHIO PHARMACEUTICALS CORP. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20230089478-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES WITH IMPROVED SYSTEMIC DELIVERY | PHIO PHARMACEUTICALS CORP. (US) | 2023-03-23 | — | — | US | disclosed |
| US-5681940-A | CONTAIN TETRAHYDROTHIOPHENE OR PYROLIDINE RINGS | ICN PHARMACEUTICALS (US) | 1997-10-28 | — | — | US | disclosed |
| EP-0789707-A1 | AMINO ACID NUCLEIC ACIDS | ICN PHARMACEUTICALS (US) | 1997-08-20 | — | — | EP | disclosed |
| EP-0789706-A1 | SUGAR MODIFIED NUCLEOSIDES AND THEIR USE FOR SYNTHESIS OF OLIGONUCLEOTIDES | ICN PHARMACEUTICALS (US) | 1997-08-20 | — | — | EP | disclosed |
| WO-1996014329-A1 | SUGAR MODIFIED NUCLEOSIDES AND THEIR USE FOR SYNTHESIS OF OLIGONUCLEOTIDES | ICN PHARMACEUTICALS (US) | 1996-05-17 | — | — | WO | disclosed |
| WO-1996014330-A1 | AMINO ACID NUCLEIC ACIDS | ICNPHARMACEUTICALS (US) | 1996-05-17 | — | — | WO | disclosed |
| US-5498522-A | ANTITUMOR AGENTS OR ANTICARCINOGENIC AGENTS | HEALTH RESEARCH, INC. (US) | 1996-03-12 | — | — | US | disclosed |
| EP-0643720-A1 | BINDING COMPETENT OLIGOMERS CONTAINING 2', 5' LINKAGES | GILEAD SCIENCES, INC. (US) | 1995-03-22 | — | — | EP | disclosed |
| WO-1993024508-A1 | BINDING COMPETENT OLIGOMERS CONTAINING 2', 5' LINKAGES | GILEAD SCIENCES, INC. (US) | 1993-12-09 | — | — | WO | disclosed |
| WO-1993010820-A1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | GILEAD SCIENCES, INC. (US) | 1993-06-10 | — | — | WO | disclosed |
| CN-1039800-A | N-2, the 3-butadienyl, three-and the tetramino alkane derivatives | MERRELL DOW PHARMA (US) | 1990-02-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11926828-B2 | Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1 | MMP1, MMP3, MMP11 | CYP2C19 4841/4885CYP1A2 4667/4885CA12 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.